Related references
Note: Only part of the references are listed.HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
Soo-Yon Rhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Instantaneous Inhibitory Potential and Inhibitory Quotient Show a Modest Association with Virologic Outcome: Is Either a Useful Surrogate for Clinical Drug Efficacy?
Rodger D. MacArthur
CLINICAL INFECTIOUS DISEASES (2010)
Instantaneous Inhibitory Potential Is Similar to Inhibitory Quotient at Predicting HIV-1 Response to Antiretroviral Therapy
Timothy J. Henrich et al.
CLINICAL INFECTIOUS DISEASES (2010)
Achieving a Quantitative Understanding of Antiretroviral Drug Efficacy
Lin Shen et al.
CLINICAL INFECTIOUS DISEASES (2010)
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance
Edward M. Gardner et al.
AIDS (2009)
Sensitivity of Phenotypic Susceptibility Analyses for Nonthymidine Nucleoside Analogues Conferred by K65R or M184V in Mixtures with Wild-Type HIV-1
Mark R. Underwood et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors
Ira B. Dicker et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
Lin Shen et al.
NATURE MEDICINE (2008)
The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions
Mian-er Cong et al.
JOURNAL OF VIROLOGY (2007)
Rationale and uses of a public HIV drug-resistance database
Robert W. Shafer
JOURNAL OF INFECTIOUS DISEASES (2006)
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects
JE Gallant et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients
H Khanlou et al.
AIDS PATIENT CARE AND STDS (2005)
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1
HL Zhang et al.
JOURNAL OF VIROLOGY (2004)
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates
JM Whitcomb et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors
T Watkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Tenofovir resistance and resensitization
K Wolf et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Human immunodeficiency virus reverse transcriptase and protease sequence database
SY Rhee et al.
NUCLEIC ACIDS RESEARCH (2003)
Fitness of drug resistant HIV-1:: methodology and clinical implications
ME Quiñones-Mateu et al.
DRUG RESISTANCE UPDATES (2002)
Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1
SH Qari et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes
B Mahalingam et al.
PROTEINS-STRUCTURE FUNCTION AND GENETICS (2001)
Viral dynamics and anti-viral pharmacodynamics:: rethinking in vitro measures of drug potency
NM Ferguson et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2001)
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
CJ Petropoulos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
F Mammano et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
